Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab.

Garcia-Valladares I, Cuchacovich R, Espinoza LR.

Drug Des Devel Ther. 2011 Jan 10;5:41-9. doi: 10.2147/DDDT.S10494. Review.

2.

New biologics for psoriasis and psoriatic arthritis.

Rozenblit M, Lebwohl M.

Dermatol Ther. 2009 Jan-Feb;22(1):56-60. doi: 10.1111/j.1529-8019.2008.01216.x. Review.

PMID:
19222517
3.

Ustekinumab: The "New Kid on the Block" in the Treatment of Psoriatic Arthritis.

Torres T, Faria R.

Drug Dev Res. 2015 Dec;76(8):428-31. doi: 10.1002/ddr.21279. Epub 2015 Sep 7.

PMID:
26372543
4.

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.

Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, Wang Y, Shen YK, Doyle MK, Mendelsohn AM, Gottlieb AB; PSUMMIT 2 Study Group.

Ann Rheum Dis. 2014 Jun;73(6):990-9. doi: 10.1136/annrheumdis-2013-204655. Epub 2014 Jan 30.

5.

Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: a systematic review.

Brezinski EA, Follansbee MR, Armstrong EJ, Armstrong AW.

Curr Pharm Des. 2014;20(4):513-28. Review.

PMID:
23565632
6.

Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents.

Weger W.

Br J Pharmacol. 2010 Jun;160(4):810-20. doi: 10.1111/j.1476-5381.2010.00702.x. Review.

7.

Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis.

Schafer JA, Kjesbo NK, Gleason PP.

J Manag Care Pharm. 2010 Jul-Aug;16(6):402-16. Review.

8.

TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.

Tobin AM, Kirby B.

BioDrugs. 2005;19(1):47-57. Review.

PMID:
15691217
9.

Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis.

Krueger G, Callis K.

Arch Dermatol. 2004 Feb;140(2):218-25. Review.

PMID:
14967799
10.

A pathogenetic approach to autoimmune skin disease therapy: psoriasis and biological drugs, unresolved issues, and future directions.

Ayroldi E, Bastianelli A, Cannarile L, Petrillo MG, Delfino DV, Fierabracci A.

Curr Pharm Des. 2011;17(29):3176-90. Review.

PMID:
21864268
11.

Inflammatory/infectious cutaneous side effects of biological drugs in patients with psoriasis: a general review with personal data.

Rongioletti F, Burlando M, Parodi A.

G Ital Dermatol Venereol. 2014 Jun;149(3):311-6. Review.

PMID:
24819758
12.

Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review.

Puig L, Morales-Múnera CE, López-Ferrer A, Geli C.

Dermatology. 2012;225(1):14-7. doi: 10.1159/000339864. Epub 2012 Aug 10. Review.

PMID:
22890275
13.

Update on TNF Inhibitors.

Kerdel FA.

Semin Cutan Med Surg. 2016 Jun;35(4 Suppl 4):S67-70. doi: 10.12788/j.sder.2016.019.

PMID:
27526035
14.

Spotlight on ustekinumab in moderate to severe plaque psoriasis.

Croxtall JD.

Am J Clin Dermatol. 2012 Apr 1;13(2):135-7. doi: 10.2165/11208650-000000000-00000.

PMID:
22201419
15.

Combination of antitumour necrosis factor-α and anti-interleukin-12/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study.

Gniadecki R, Bang B, Sand C.

Br J Dermatol. 2016 May;174(5):1145-6. doi: 10.1111/bjd.14270. Epub 2016 May 4. No abstract available.

PMID:
26522308
16.

Combination therapy of biologics with traditional agents in psoriasis.

Guenther LC.

Skin Therapy Lett. 2011 Jun;16(6):1-3.

17.

Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases.

de Souza A, Ali-Shaw T, Reddy SM, Fiorentino D, Strober BE.

Br J Dermatol. 2013 Jan;168(1):210-2. doi: 10.1111/j.1365-2133.2012.11206.x.

PMID:
23278559
18.

Treatment of psoriasis and psoriatic arthritis.

Papoutsaki M, Costanzo A.

BioDrugs. 2013 Jan;27 Suppl 1:3-12. doi: 10.1007/BF03325637. Review.

PMID:
23990277
19.

Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.

Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ.

J Manag Care Pharm. 2013 Oct;19(8):621-30.

20.

New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab.

Kurzeja M, Rudnicka L, Olszewska M.

Am J Clin Dermatol. 2011 Apr 1;12(2):113-25. doi: 10.2165/11538950-000000000-00000. Review.

PMID:
21348542

Supplemental Content

Support Center